Please login to the form below

Not currently logged in
Email:
Password:

Mundipharma

This page shows the latest Mundipharma news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar

Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar

GlobalData predicts Trazimera can earn $9m in its first year, far behind the forecast 12 month totals for Celltrion and Mundipharma’s Herzuma ($59m), Amgen’s Kanjinti ($33m), and Samsung Bioepsis

Latest news

More from news
Approximately 9 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Finally it is always encouraging to see medium size companies like Mundipharma and Jazz finding and licensing new product opportunities. ... Mundipharma built its oncology franchise following the acquisition of an old anti-cancer drug and the deal to

  • When science is not enough When science is not enough

    When science is not enough. Mundipharma’s Will Dunlop on a new framework to guide development programmes to a better destination. ... programme, ”says Will Dunlop, head of market access for Mundipharma International, who has been developing the

  • Deal Watch October 2016 Deal Watch October 2016

    For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Divestment of US rights. 1, 050. Esteve/ Mundipharma. Discovery and development of next generation pain products including E-52862 in P2 for neuropathic pain.

More from intelligence
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Mundipharma appoints Dr Alberto Martinez as president and CEO Mundipharma appoints Dr Alberto Martinez as president and CEO

    His new role will see him take responsibility for strengthening Mundipharma ’s network in Europe and focus on its alliances. ... Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.

  • Mundipharma appoints chief information officer Mundipharma appoints chief information officer

    Mundipharma appoints chief information officer. Philippe Mazas joins the UK-based pharma network from Smith &Nephew. ... His new role will see him take responsibility for the IT services provided to Mundipharma ’s global network of associated companies.

  • Hywel Day joins Napp Pharmaceuticals Hywel Day joins Napp Pharmaceuticals

    Hywel Day joins Napp Pharmaceuticals. Moves from Mundipharma to take up managing director role. ... It’s a return to Napp for Day, who spent 10 years at Napp from 2003, before moving to Mundipharma.

  • Napp names new managing director Napp names new managing director

    Napp names new managing director. Alberto Martinez joins from Mundipharma. UK-based Napp Pharmaceuticals has appointed Alberto Martinez as the company's new managing director. ... Martinez's previous experience includes time as marketing manager at

  • Aurora expands team Aurora expands team

    Clients include Boehringer Ingelheim, Mundipharma and Novartis.

More from appointments
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics